Humanigen HGEN Stock News

Humanigen Inc (OTCMKTS: HGEN) is likely to make a run for the top in the market this morning, and for good reason. The company released data that shows that tis COVID-19 treatment is incredibly effective in severely ill patients. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

HGEN Stock To Heat Up On COVID-19 Treatment News

In the press release, Humanigen announced data with regard to the first clinical use of its lenzilumab candidate in COVID-19 patients. In the release, the company said taht 12 COVID-19 patients have been treated.

Importantly, patients provided with lenzilumab showed rapid clinical improvement with a median recovery time of five days. Also, median time to discharge came in at five days with the treatment leading to a 100% survival rate to the data cut-off date.

Importantly, HGEN said that all patients included showed rapid improvement in oxygenation, temperature, inflammatory cytokines and key hematological parameters consistent with improved clinical outcomes.

In a statement, Dr. Zelalem Temesgen, Professor of Medicine at the Mayo Clinic (the clinic where the study was hosted) and one of the key authors of the study, had the following to offer:

Lenzilumab use was associated with improved clinical outcomes and oxygen requirement, with no reported mortality. We did not observe any treatment-emergent adverse events attributable to lenzilumab and it was well-tolerated. Based on the pathophysiology of cytokine storm following SARS-CoV-2 infection, along with work conducted at Mayo Clinic on GM-CSF depletion in CAR-T therapy, lenzilumab may offer a rational approach to ameliorate the consequences of cytokine storm in COVID-19.

The above statement was followed up by Dr. Cameron Durrant, CEO At HGEN. Here’s what he had to say:

It is extremely encouraging to see this initial group of high-risk patients with severe and critical COVID-19 pneumonia show clinical improvement on lenzilumab, and at the data cut-off point, 11 of them discharged from the hospital. All 12 patients had at least one risk factor associated with poor outcomes, such as age, smoking history, cardiovascular disease, diabetes, chronic kidney disease, chronic lung disease, high BMI, and elevated inflammatory markers, with several patients having multiple such risk factors.

This Data Is Huge

As we all know, for the COVID-19 pandemic to find its way to the past, we need to have viable treatments for those that do fall ill. Importantly, all patients included in the study were hospitalized in the Mayo Clinic system. Moreover all of these patients had severe or critical pneumonia as a result of COVID-19.

So, we’re not just talking about COVID-19 patients, we are talking about patients that were severely ill. Moreover, for these patients to qualify for the Humanigen study, they were considered high risk of further disease progression.

These patients needed oxygen supplementation and had elevation in at least one inflammatory biomarker prior to receiving the drug. Moreover, all patients had at least one co-morbidity associted with poor outcomes in COVID-19 and several had multiple co-morbidities.

Nonetheless, in this high risk, severely sick population, HGEN proved that its lenzilumab worked 100% of the time, getting patients from very sick to discharge from the hospital in around five days. That’s valuable my friends.

This is much better than any data we’ve seen about any other drug under development for COVID-19 patients. As such, investors should be paying close attention to HGEN stock.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.